JP2000513720A - 修飾された第ｖｉｉ因子 - Google Patents

修飾された第ｖｉｉ因子

Info

Publication number: JP2000513720A
Authority: JP; Japan
Prior art keywords: factor; factor vii; phe; dansyl; protease inhibitor
Prior art date: 1996-06-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

JP10501082A

Other languages

English (en)

Japanese (ja)

Other versions

JP2000513720A5 (2

Inventor

クリスチャンペテルセン，ラルス

イー．ハート，チャールズ

ヘッドネル，ウッラ

エズバンラスムッセン，ミレラ

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novo Nordisk AS

Original Assignee

Novo Nordisk AS

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-06-07

Filing date

1997-06-06

Publication date

2000-10-17

1997-06-06 Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS

2000-10-17 Publication of JP2000513720A publication Critical patent/JP2000513720A/ja

2005-03-10 Publication of JP2000513720A5 publication Critical patent/JP2000513720A5/ja

Status Ceased legal-status Critical Current

Links

229940012413 factor vii Drugs 0.000 title claims abstract description 172
108010023321 Factor VII Proteins 0.000 title claims abstract description 171
102100023804 Coagulation factor VII Human genes 0.000 title claims abstract description 168
238000000034 method Methods 0.000 claims abstract description 78
230000010410 reperfusion Effects 0.000 claims abstract description 44
108010014173 Factor X Proteins 0.000 claims abstract description 39
208000007536 Thrombosis Diseases 0.000 claims abstract description 39
230000002792 vascular Effects 0.000 claims abstract description 35
230000015572 biosynthetic process Effects 0.000 claims abstract description 31
230000003197 catalytic effect Effects 0.000 claims abstract description 31
230000004048 modification Effects 0.000 claims abstract description 27
238000012986 modification Methods 0.000 claims abstract description 27
230000017531 blood circulation Effects 0.000 claims abstract description 25
108010076282 Factor IX Proteins 0.000 claims abstract description 23
229960004222 factor ix Drugs 0.000 claims abstract description 22
230000002107 myocardial effect Effects 0.000 claims abstract description 18
150000001875 compounds Chemical class 0.000 claims abstract description 10
230000003680 myocardial damage Effects 0.000 claims abstract description 9
239000000203 mixture Substances 0.000 claims description 57
208000014674 injury Diseases 0.000 claims description 27
238000002399 angioplasty Methods 0.000 claims description 20
238000004519 manufacturing process Methods 0.000 claims description 20
230000002829 reductive effect Effects 0.000 claims description 19
238000001356 surgical procedure Methods 0.000 claims description 19
108090000765 processed proteins & peptides Proteins 0.000 claims description 16
230000008733 trauma Effects 0.000 claims description 13
230000002401 inhibitory effect Effects 0.000 claims description 12
238000002360 preparation method Methods 0.000 claims description 12
239000003814 drug Substances 0.000 claims description 11
UFXAQJOOAQICNE-HKBOAZHASA-N (2r)-2-amino-n-[(2s)-2-[[(3s)-1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]amino]-3-phenylpropanoyl]-3-phenylpropanamide Chemical compound C([C@@H](N)C(=O)NC(=O)[C@H](CC=1C=CC=CC=1)N[C@@H](CCCN=C(N)N)C(=O)CCl)C1=CC=CC=C1 UFXAQJOOAQICNE-HKBOAZHASA-N 0.000 claims description 10
-1 halomethyl ketone Chemical class 0.000 claims description 9
150000002903 organophosphorus compounds Chemical class 0.000 claims description 8
LDMSFLLWFAFZAF-OALUTQOASA-N (4s)-5-[[2-[[(3s)-1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]amino]-2-oxoethyl]amino]-4-[[5-(dimethylamino)naphthalen-1-yl]sulfonylamino]-5-oxopentanoic acid Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(=O)(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)CCl LDMSFLLWFAFZAF-OALUTQOASA-N 0.000 claims description 7
BHBIPLOIWQSVID-UHFFFAOYSA-N thiohypofluorous acid Chemical compound SF BHBIPLOIWQSVID-UHFFFAOYSA-N 0.000 claims description 7
208000037891 myocardial injury Diseases 0.000 claims description 5
238000002406 microsurgery Methods 0.000 claims description 4
208000010125 myocardial infarction Diseases 0.000 claims description 3
150000002576 ketones Chemical class 0.000 claims description 2
229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 12
239000000137 peptide hydrolase inhibitor Substances 0.000 claims 12
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 10
229940122055 Serine protease inhibitor Drugs 0.000 claims 6
101710102218 Serine protease inhibitor Proteins 0.000 claims 6
239000003001 serine protease inhibitor Substances 0.000 claims 6
108010071623 chloropeptide Proteins 0.000 claims 5
230000000144 pharmacologic effect Effects 0.000 claims 1
229920002477 rna polymer Polymers 0.000 claims 1
229940124597 therapeutic agent Drugs 0.000 claims 1
229940012414 factor viia Drugs 0.000 abstract description 123
108010054265 Factor VIIa Proteins 0.000 abstract description 74
230000023555 blood coagulation Effects 0.000 abstract description 4
230000003213 activating effect Effects 0.000 abstract description 3
210000004027 cell Anatomy 0.000 description 86
108010000499 Thromboplastin Proteins 0.000 description 75
102000002262 Thromboplastin Human genes 0.000 description 75
241001465754 Metazoa Species 0.000 description 72
230000000694 effects Effects 0.000 description 62
108090000623 proteins and genes Proteins 0.000 description 47
230000015271 coagulation Effects 0.000 description 39
238000005345 coagulation Methods 0.000 description 39
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 38
108010074860 Factor Xa Proteins 0.000 description 31
229940012426 factor x Drugs 0.000 description 31
238000011282 treatment Methods 0.000 description 30
241000283973 Oryctolagus cuniculus Species 0.000 description 29
235000018102 proteins Nutrition 0.000 description 29
102000004169 proteins and genes Human genes 0.000 description 29
239000000243 solution Substances 0.000 description 28
230000006378 damage Effects 0.000 description 27
108020004414 DNA Proteins 0.000 description 25
230000005764 inhibitory process Effects 0.000 description 25
235000002639 sodium chloride Nutrition 0.000 description 23
206010061216 Infarction Diseases 0.000 description 22
210000004369 blood Anatomy 0.000 description 22
239000008280 blood Substances 0.000 description 22
230000007574 infarction Effects 0.000 description 22
150000001413 amino acids Chemical group 0.000 description 21
239000011780 sodium chloride Substances 0.000 description 21
230000004913 activation Effects 0.000 description 20
230000001965 increasing effect Effects 0.000 description 20
238000002347 injection Methods 0.000 description 20
239000007924 injection Substances 0.000 description 20
239000000523 sample Substances 0.000 description 20
230000035602 clotting Effects 0.000 description 19
210000001519 tissue Anatomy 0.000 description 19
208000027418 Wounds and injury Diseases 0.000 description 18
238000003556 assay Methods 0.000 description 18
239000012634 fragment Substances 0.000 description 17
238000001802 infusion Methods 0.000 description 17
210000000329 smooth muscle myocyte Anatomy 0.000 description 17
206010053567 Coagulopathies Diseases 0.000 description 16
235000001014 amino acid Nutrition 0.000 description 16
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 15
239000003146 anticoagulant agent Substances 0.000 description 15
210000001367 artery Anatomy 0.000 description 15
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 14
208000024248 Vascular System injury Diseases 0.000 description 14
208000012339 Vascular injury Diseases 0.000 description 14
229920000669 heparin Polymers 0.000 description 14
229960002897 heparin Drugs 0.000 description 14
239000002609 medium Substances 0.000 description 14
241001504519 Papio ursinus Species 0.000 description 13
229940127219 anticoagulant drug Drugs 0.000 description 13
230000000302 ischemic effect Effects 0.000 description 13
238000012360 testing method Methods 0.000 description 13
210000004204 blood vessel Anatomy 0.000 description 12
238000006243 chemical reaction Methods 0.000 description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
238000005259 measurement Methods 0.000 description 12
210000004165 myocardium Anatomy 0.000 description 12
239000012266 salt solution Substances 0.000 description 12
UVKLGXYYCWVGIK-UEHPTQOCSA-N (4s)-5-[[2-[[(1s)-1-carboxy-4-(diaminomethylideneamino)butyl]amino]-2-oxoethyl]amino]-3-(chloromethyl)-4-[[5-(dimethylamino)naphthalen-1-yl]sulfonylamino]-5-oxopentanoic acid Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(=O)(=O)N[C@@H](C(CCl)CC(O)=O)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(O)=O UVKLGXYYCWVGIK-UEHPTQOCSA-N 0.000 description 11
108010094028 Prothrombin Proteins 0.000 description 11
241000700159 Rattus Species 0.000 description 11
108090000190 Thrombin Proteins 0.000 description 11
239000000872 buffer Substances 0.000 description 11
230000008021 deposition Effects 0.000 description 11
201000010099 disease Diseases 0.000 description 11
231100000673 dose–response relationship Toxicity 0.000 description 11
208000037803 restenosis Diseases 0.000 description 11
238000006467 substitution reaction Methods 0.000 description 11
229960004072 thrombin Drugs 0.000 description 11
241000283690 Bos taurus Species 0.000 description 10
206010011086 Coronary artery occlusion Diseases 0.000 description 10
102100027378 Prothrombin Human genes 0.000 description 10
239000007983 Tris buffer Substances 0.000 description 10
238000007792 addition Methods 0.000 description 10
230000027455 binding Effects 0.000 description 10
238000005516 engineering process Methods 0.000 description 10
238000002474 experimental method Methods 0.000 description 10
230000009805 platelet accumulation Effects 0.000 description 10
229940039716 prothrombin Drugs 0.000 description 10
241000894007 species Species 0.000 description 10
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 10
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 9
208000032843 Hemorrhage Diseases 0.000 description 9
230000001154 acute effect Effects 0.000 description 9
208000034158 bleeding Diseases 0.000 description 9
230000000740 bleeding effect Effects 0.000 description 9
210000001715 carotid artery Anatomy 0.000 description 9
230000007423 decrease Effects 0.000 description 9
230000001419 dependent effect Effects 0.000 description 9
229940079593 drug Drugs 0.000 description 9
210000002889 endothelial cell Anatomy 0.000 description 9
238000011534 incubation Methods 0.000 description 9
208000028867 ischemia Diseases 0.000 description 9
239000003550 marker Substances 0.000 description 9
230000008569 process Effects 0.000 description 9
230000009885 systemic effect Effects 0.000 description 9
102000009123 Fibrin Human genes 0.000 description 8
108010073385 Fibrin Proteins 0.000 description 8
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 8
229930003448 Vitamin K Natural products 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
239000003593 chromogenic compound Substances 0.000 description 8
210000004351 coronary vessel Anatomy 0.000 description 8
238000010790 dilution Methods 0.000 description 8
239000012895 dilution Substances 0.000 description 8
239000013604 expression vector Substances 0.000 description 8
210000001105 femoral artery Anatomy 0.000 description 8
229950003499 fibrin Drugs 0.000 description 8
210000002216 heart Anatomy 0.000 description 8
210000005240 left ventricle Anatomy 0.000 description 8
239000004005 microsphere Substances 0.000 description 8
230000010412 perfusion Effects 0.000 description 8
SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 8
230000008488 polyadenylation Effects 0.000 description 8
230000009261 transgenic effect Effects 0.000 description 8
235000019168 vitamin K Nutrition 0.000 description 8
239000011712 vitamin K Substances 0.000 description 8
229940046010 vitamin k Drugs 0.000 description 8
108091003079 Bovine Serum Albumin Proteins 0.000 description 7
108010060630 Lactoglobulins Proteins 0.000 description 7
108010011756 Milk Proteins Proteins 0.000 description 7
241000282520 Papio Species 0.000 description 7
241001494479 Pecora Species 0.000 description 7
230000002785 anti-thrombosis Effects 0.000 description 7
210000000709 aorta Anatomy 0.000 description 7
238000013171 endarterectomy Methods 0.000 description 7
210000004962 mammalian cell Anatomy 0.000 description 7
239000001103 potassium chloride Substances 0.000 description 7
235000011164 potassium chloride Nutrition 0.000 description 7
239000000126 substance Substances 0.000 description 7
230000002537 thrombolytic effect Effects 0.000 description 7
239000013598 vector Substances 0.000 description 7
150000003721 vitamin K derivatives Chemical class 0.000 description 7
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
102000004411 Antithrombin III Human genes 0.000 description 6
108090000935 Antithrombin III Proteins 0.000 description 6
241000282472 Canis lupus familiaris Species 0.000 description 6
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
108010062466 Enzyme Precursors Proteins 0.000 description 6
102000010911 Enzyme Precursors Human genes 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
206010047249 Venous thrombosis Diseases 0.000 description 6
238000002835 absorbance Methods 0.000 description 6
229960005348 antithrombin iii Drugs 0.000 description 6
230000000875 corresponding effect Effects 0.000 description 6
238000009826 distribution Methods 0.000 description 6
229940099816 human factor vii Drugs 0.000 description 6
238000003780 insertion Methods 0.000 description 6
230000037431 insertion Effects 0.000 description 6
230000001404 mediated effect Effects 0.000 description 6
235000013336 milk Nutrition 0.000 description 6
239000008267 milk Substances 0.000 description 6
210000004080 milk Anatomy 0.000 description 6
230000014508 negative regulation of coagulation Effects 0.000 description 6
230000036961 partial effect Effects 0.000 description 6
230000037361 pathway Effects 0.000 description 6
239000008194 pharmaceutical composition Substances 0.000 description 6
239000013612 plasmid Substances 0.000 description 6
230000009467 reduction Effects 0.000 description 6
230000004044 response Effects 0.000 description 6
239000006152 selective media Substances 0.000 description 6
210000004509 vascular smooth muscle cell Anatomy 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
102100022641 Coagulation factor IX Human genes 0.000 description 5
241000282412 Homo Species 0.000 description 5
108091028043 Nucleic acid sequence Proteins 0.000 description 5
230000033115 angiogenesis Effects 0.000 description 5
239000005557 antagonist Substances 0.000 description 5
230000004087 circulation Effects 0.000 description 5
238000007820 coagulation assay Methods 0.000 description 5
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
230000012010 growth Effects 0.000 description 5
239000001963 growth medium Substances 0.000 description 5
210000004731 jugular vein Anatomy 0.000 description 5
239000002953 phosphate buffered saline Substances 0.000 description 5
108091033319 polynucleotide Proteins 0.000 description 5
102000040430 polynucleotide Human genes 0.000 description 5
238000000746 purification Methods 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
239000000758 substrate Substances 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
239000011534 wash buffer Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
102000004506 Blood Proteins Human genes 0.000 description 4
108010017384 Blood Proteins Proteins 0.000 description 4
108091026890 Coding region Proteins 0.000 description 4
206010051055 Deep vein thrombosis Diseases 0.000 description 4
241000393496 Electra Species 0.000 description 4
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
102000014171 Milk Proteins Human genes 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 4
206010052428 Wound Diseases 0.000 description 4
206010000891 acute myocardial infarction Diseases 0.000 description 4
230000003872 anastomosis Effects 0.000 description 4
239000000427 antigen Substances 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
230000004872 arterial blood pressure Effects 0.000 description 4
230000008901 benefit Effects 0.000 description 4
230000008859 change Effects 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
230000002860 competitive effect Effects 0.000 description 4
238000012217 deletion Methods 0.000 description 4
230000037430 deletion Effects 0.000 description 4
210000001671 embryonic stem cell Anatomy 0.000 description 4
230000006624 extrinsic pathway Effects 0.000 description 4
239000012894 fetal calf serum Substances 0.000 description 4
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
230000000977 initiatory effect Effects 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
229960003299 ketamine Drugs 0.000 description 4
239000010410 layer Substances 0.000 description 4
108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 4
244000144972 livestock Species 0.000 description 4
235000021239 milk protein Nutrition 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
230000003204 osmotic effect Effects 0.000 description 4
239000002985 plastic film Substances 0.000 description 4
239000002157 polynucleotide Substances 0.000 description 4
238000007619 statistical method Methods 0.000 description 4
230000000699 topical effect Effects 0.000 description 4
241000701161 unidentified adenovirus Species 0.000 description 4
KWPACVJPAFGBEQ-IKGGRYGDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(3s)-1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]pyrrolidine-2-carboxamide Chemical group C([C@@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)CCl)C1=CC=CC=C1 KWPACVJPAFGBEQ-IKGGRYGDSA-N 0.000 description 3
KQJTXYQXRHCWKW-PJSBSAQXSA-N (4s)-4-[[(2s,3s)-2-benzamido-3-methylpentanoyl]amino]-5-[[2-[[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-5-oxopentanoic acid;hydrochloride Chemical compound Cl.N([C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C1=CC=CC=C1 KQJTXYQXRHCWKW-PJSBSAQXSA-N 0.000 description 3
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
206010002091 Anaesthesia Diseases 0.000 description 3
201000001320 Atherosclerosis Diseases 0.000 description 3
206010010904 Convulsion Diseases 0.000 description 3
208000001778 Coronary Occlusion Diseases 0.000 description 3
241000699800 Cricetinae Species 0.000 description 3
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
239000007995 HEPES buffer Substances 0.000 description 3
241000701109 Human adenovirus 2 Species 0.000 description 3
108091092195 Intron Proteins 0.000 description 3
102000008192 Lactoglobulins Human genes 0.000 description 3
241000208474 Protea Species 0.000 description 3
241000555745 Sciuridae Species 0.000 description 3
108010022394 Threonine synthase Proteins 0.000 description 3
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 3
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 3
241000700605 Viruses Species 0.000 description 3
239000012190 activator Substances 0.000 description 3
230000003024 amidolytic effect Effects 0.000 description 3
230000037005 anaesthesia Effects 0.000 description 3
238000002583 angiography Methods 0.000 description 3
238000010171 animal model Methods 0.000 description 3
239000008365 aqueous carrier Substances 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
108010031969 benzoyl-Ile-Glu-Gly-Arg-p-nitroanilide Proteins 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
229910001424 calcium ion Inorganic materials 0.000 description 3
238000013172 carotid endarterectomy Methods 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
239000000306 component Substances 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
230000029087 digestion Effects 0.000 description 3
102000004419 dihydrofolate reductase Human genes 0.000 description 3
238000001647 drug administration Methods 0.000 description 3
235000013601 eggs Nutrition 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
239000012091 fetal bovine serum Substances 0.000 description 3
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 3
229960003132 halothane Drugs 0.000 description 3
230000000004 hemodynamic effect Effects 0.000 description 3
230000023597 hemostasis Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000003993 interaction Effects 0.000 description 3
210000005246 left atrium Anatomy 0.000 description 3
210000005075 mammary gland Anatomy 0.000 description 3
239000000463 material Substances 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
239000012528 membrane Substances 0.000 description 3
230000005012 migration Effects 0.000 description 3
238000013508 migration Methods 0.000 description 3
210000001616 monocyte Anatomy 0.000 description 3
230000000877 morphologic effect Effects 0.000 description 3
210000000440 neutrophil Anatomy 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 3
150000003904 phospholipids Chemical class 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
230000000069 prophylactic effect Effects 0.000 description 3
108700038606 rat Smooth muscle Proteins 0.000 description 3
238000011160 research Methods 0.000 description 3
238000002271 resection Methods 0.000 description 3
230000007017 scission Effects 0.000 description 3
239000011734 sodium Substances 0.000 description 3
238000010186 staining Methods 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
229960000187 tissue plasminogen activator Drugs 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
210000003462 vein Anatomy 0.000 description 3
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 3
229960001600 xylazine Drugs 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
WFFZGYRTVIPBFN-UHFFFAOYSA-N 3h-indene-1,2-dione Chemical compound C1=CC=C2C(=O)C(=O)CC2=C1 WFFZGYRTVIPBFN-UHFFFAOYSA-N 0.000 description 2
206010002388 Angina unstable Diseases 0.000 description 2
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
108010081589 Becaplermin Proteins 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
241000283707 Capra Species 0.000 description 2
206010011091 Coronary artery thrombosis Diseases 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
108091029865 Exogenous DNA Proteins 0.000 description 2
108010049003 Fibrinogen Proteins 0.000 description 2
102000008946 Fibrinogen Human genes 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
206010028851 Necrosis Diseases 0.000 description 2
240000007594 Oryza sativa Species 0.000 description 2
235000007164 Oryza sativa Nutrition 0.000 description 2
229930040373 Paraformaldehyde Natural products 0.000 description 2
208000031481 Pathologic Constriction Diseases 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
239000004743 Polypropylene Substances 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
101800004937 Protein C Proteins 0.000 description 2
102000017975 Protein C Human genes 0.000 description 2
229940096437 Protein S Drugs 0.000 description 2
102000029301 Protein S Human genes 0.000 description 2
108010066124 Protein S Proteins 0.000 description 2
108010076504 Protein Sorting Signals Proteins 0.000 description 2
208000010378 Pulmonary Embolism Diseases 0.000 description 2
239000012083 RIPA buffer Substances 0.000 description 2
108020005067 RNA Splice Sites Proteins 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
101800001700 Saposin-D Proteins 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
208000007814 Unstable Angina Diseases 0.000 description 2
230000035508 accumulation Effects 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000002411 adverse Effects 0.000 description 2
230000004075 alteration Effects 0.000 description 2
230000003321 amplification Effects 0.000 description 2
238000005571 anion exchange chromatography Methods 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000008321 arterial blood flow Effects 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
229910052788 barium Inorganic materials 0.000 description 2
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 2
RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
239000012503 blood component Substances 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
230000036760 body temperature Effects 0.000 description 2
210000002302 brachial artery Anatomy 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
238000010367 cloning Methods 0.000 description 2
239000000701 coagulant Substances 0.000 description 2
230000005757 colony formation Effects 0.000 description 2
239000003636 conditioned culture medium Substances 0.000 description 2
210000002808 connective tissue Anatomy 0.000 description 2
230000036461 convulsion Effects 0.000 description 2
208000002528 coronary thrombosis Diseases 0.000 description 2
238000012937 correction Methods 0.000 description 2
230000007547 defect Effects 0.000 description 2
229960003964 deoxycholic acid Drugs 0.000 description 2
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
238000001212 derivatisation Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
235000021186 dishes Nutrition 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
230000003511 endothelial effect Effects 0.000 description 2
210000003038 endothelium Anatomy 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
229940012952 fibrinogen Drugs 0.000 description 2
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
210000002837 heart atrium Anatomy 0.000 description 2
RBTKNAXYKSUFRK-UHFFFAOYSA-N heliogen blue Chemical compound [Cu].[N-]1C2=C(C=CC=C3)C3=C1N=C([N-]1)C3=CC=CC=C3C1=NC([N-]1)=C(C=CC=C3)C3=C1N=C([N-]1)C3=CC=CC=C3C1=N2 RBTKNAXYKSUFRK-UHFFFAOYSA-N 0.000 description 2
206010073071 hepatocellular carcinoma Diseases 0.000 description 2
206010020718 hyperplasia Diseases 0.000 description 2
238000010191 image analysis Methods 0.000 description 2
201000004332 intermediate coronary syndrome Diseases 0.000 description 2
230000006623 intrinsic pathway Effects 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
210000003292 kidney cell Anatomy 0.000 description 2
230000002147 killing effect Effects 0.000 description 2
238000002647 laser therapy Methods 0.000 description 2
210000003041 ligament Anatomy 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
230000035772 mutation Effects 0.000 description 2
230000017074 necrotic cell death Effects 0.000 description 2
239000013642 negative control Substances 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
229920002866 paraformaldehyde Polymers 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
229960001412 pentobarbital Drugs 0.000 description 2
229920000573 polyethylene Polymers 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
229920001155 polypropylene Polymers 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
238000011809 primate model Methods 0.000 description 2
239000000047 product Substances 0.000 description 2
229960000856 protein c Drugs 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
238000003156 radioimmunoprecipitation Methods 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
108010013773 recombinant FVIIa Proteins 0.000 description 2
230000000306 recurrent effect Effects 0.000 description 2
235000009566 rice Nutrition 0.000 description 2
102220047090 rs6152 Human genes 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
230000028327 secretion Effects 0.000 description 2
229920000260 silastic Polymers 0.000 description 2
239000001509 sodium citrate Substances 0.000 description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
230000036262 stenosis Effects 0.000 description 2
208000037804 stenosis Diseases 0.000 description 2
238000003860 storage Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
230000001732 thrombotic effect Effects 0.000 description 2
238000001890 transfection Methods 0.000 description 2
230000003827 upregulation Effects 0.000 description 2
230000003966 vascular damage Effects 0.000 description 2
238000007631 vascular surgery Methods 0.000 description 2
210000005166 vasculature Anatomy 0.000 description 2
230000035899 viability Effects 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
229940088594 vitamin Drugs 0.000 description 2
229930003231 vitamin Natural products 0.000 description 2
239000011782 vitamin Substances 0.000 description 2
235000013343 vitamin Nutrition 0.000 description 2
238000005406 washing Methods 0.000 description 2
XHTORJWGZKCDGL-GRGSLBFTSA-N (2s)-1-[(2r,3r)-2-amino-3-methylpentanoyl]-n-[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]pyrrolidine-2-carboxamide Chemical compound CC[C@@H](C)[C@@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC1=CC=C([N+]([O-])=O)C=C1 XHTORJWGZKCDGL-GRGSLBFTSA-N 0.000 description 1
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 1
CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
108020005029 5' Flanking Region Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
206010003162 Arterial injury Diseases 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
206010004053 Bacterial toxaemia Diseases 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
241000167854 Bourreria succulenta Species 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
101100439299 Caenorhabditis elegans cgt-3 gene Proteins 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
240000001432 Calendula officinalis Species 0.000 description 1
235000005881 Calendula officinalis Nutrition 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
108090000317 Chymotrypsin Proteins 0.000 description 1
101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
208000002330 Congenital Heart Defects Diseases 0.000 description 1
241000501458 Cultus Species 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
108010014258 Elastin Proteins 0.000 description 1
102000016942 Elastin Human genes 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
108010048049 Factor IXa Proteins 0.000 description 1
108010014172 Factor V Proteins 0.000 description 1
108010061932 Factor VIIIa Proteins 0.000 description 1
108010071241 Factor XIIa Proteins 0.000 description 1
229940123583 Factor Xa inhibitor Drugs 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical group OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
229920002971 Heparan sulfate Polymers 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
206010020843 Hyperthermia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108700005091 Immunoglobulin Genes Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
241000408495 Iton Species 0.000 description 1
102000004407 Lactalbumin Human genes 0.000 description 1
108090000942 Lactalbumin Proteins 0.000 description 1
208000010718 Multiple Organ Failure Diseases 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
208000032026 No-Reflow Phenomenon Diseases 0.000 description 1
108091092724 Noncoding DNA Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
101001021261 Pedobacter heparinus (strain ATCC 13125 / DSM 2366 / CIP 104194 / JCM 7457 / NBRC 12017 / NCIMB 9290 / NRRL B-14731 / HIM 762-3) Heparin and heparin-sulfate lyase Proteins 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
241000287462 Phalacrocorax carbo Species 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
101710103506 Platelet-derived growth factor subunit A Proteins 0.000 description 1
208000004550 Postoperative Pain Diseases 0.000 description 1
108010051508 Preconativ Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
206010067171 Regurgitation Diseases 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
206010040483 Sexual inhibition Diseases 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
208000007718 Stable Angina Diseases 0.000 description 1
108010023197 Streptokinase Proteins 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
208000013222 Toxemia Diseases 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
208000032594 Vascular Remodeling Diseases 0.000 description 1
206010047163 Vasospasm Diseases 0.000 description 1
101710087237 Whey acidic protein Proteins 0.000 description 1
238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
229920002494 Zein Polymers 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
239000000556 agonist Substances 0.000 description 1
238000007605 air drying Methods 0.000 description 1
238000003277 amino acid sequence analysis Methods 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
239000002506 anticoagulant protein Substances 0.000 description 1
230000010100 anticoagulation Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
210000002376 aorta thoracic Anatomy 0.000 description 1
238000013459 approach Methods 0.000 description 1
229940006612 barium citrate Drugs 0.000 description 1
PAVWOHWZXOQYDB-UHFFFAOYSA-H barium(2+);2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Ba+2].[Ba+2].[Ba+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PAVWOHWZXOQYDB-UHFFFAOYSA-H 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000036782 biological activation Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
238000004820 blood count Methods 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
244000309464 bull Species 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
238000006473 carboxylation reaction Methods 0.000 description 1
210000001168 carotid artery common Anatomy 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
210000003850 cellular structure Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000035605 chemotaxis Effects 0.000 description 1
235000019693 cherries Nutrition 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229960002376 chymotrypsin Drugs 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
210000003109 clavicle Anatomy 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
229940105772 coagulation factor vii Drugs 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000004020 conductor Substances 0.000 description 1
208000028831 congenital heart disease Diseases 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
238000005138 cryopreservation Methods 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
235000013365 dairy product Nutrition 0.000 description 1
230000034994 death Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
229920002549 elastin Polymers 0.000 description 1
239000012149 elution buffer Substances 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000013401 experimental design Methods 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000003527 fibrinolytic agent Substances 0.000 description 1
238000010304 firing Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
230000006251 gamma-carboxylation Effects 0.000 description 1
238000007429 general method Methods 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000003292 glue Substances 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
230000036449 good health Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
125000004970 halomethyl group Chemical group 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
230000002439 hemostatic effect Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
230000036031 hyperthermia Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000003317 immunochromatography Methods 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
238000009434 installation Methods 0.000 description 1
230000003601 intercostal effect Effects 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
239000013038 irreversible inhibitor Substances 0.000 description 1
230000007794 irritation Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
108010075079 isoleucyl-prolyl-arginine-4-nitroanilide Proteins 0.000 description 1
229960004184 ketamine hydrochloride Drugs 0.000 description 1
238000002372 labelling Methods 0.000 description 1
229960004194 lidocaine Drugs 0.000 description 1
230000003859 lipid peroxidation Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000006166 lysate Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
210000004088 microvessel Anatomy 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
238000007491 morphometric analysis Methods 0.000 description 1
230000008345 muscle blood flow Effects 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
231100000219 mutagenic Toxicity 0.000 description 1
230000003505 mutagenic effect Effects 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
229940105631 nembutal Drugs 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000011587 new zealand white rabbit Methods 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
230000000414 obstructive effect Effects 0.000 description 1
210000003101 oviduct Anatomy 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
210000003516 pericardium Anatomy 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000008055 phosphate buffer solution Substances 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
JOHZPMXAZQZXHR-UHFFFAOYSA-N pipemidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCNCC1 JOHZPMXAZQZXHR-UHFFFAOYSA-N 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920006255 plastic film Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
230000031915 positive regulation of coagulation Effects 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000003805 procoagulant Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
238000000164 protein isolation Methods 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
210000001747 pupil Anatomy 0.000 description 1
230000000384 rearing effect Effects 0.000 description 1
229940068953 recombinant fviia Drugs 0.000 description 1
238000002278 reconstructive surgery Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000000611 regression analysis Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
210000004994 reproductive system Anatomy 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
229940021384 salt irrigating solution Drugs 0.000 description 1
230000036573 scar formation Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
230000036301 sexual development Effects 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
238000004904 shortening Methods 0.000 description 1
238000001629 sign test Methods 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
238000012868 site-directed mutagenesis technique Methods 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000001540 sodium lactate Substances 0.000 description 1
229940005581 sodium lactate Drugs 0.000 description 1
235000011088 sodium lactate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
238000000527 sonication Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000012421 spiking Methods 0.000 description 1
238000005507 spraying Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
229960005202 streptokinase Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
OBTWBSRJZRCYQV-UHFFFAOYSA-N sulfuryl difluoride Chemical compound FS(F)(=O)=O OBTWBSRJZRCYQV-UHFFFAOYSA-N 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
230000009424 thromboembolic effect Effects 0.000 description 1
229960000103 thrombolytic agent Drugs 0.000 description 1
230000009772 tissue formation Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
210000004231 tunica media Anatomy 0.000 description 1
230000007306 turnover Effects 0.000 description 1
229940072651 tylenol Drugs 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
231100000216 vascular lesion Toxicity 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
208000003663 ventricular fibrillation Diseases 0.000 description 1
108700026220 vif Genes Proteins 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
239000002699 waste material Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
229940072358 xylocaine Drugs 0.000 description 1
239000005019 zein Substances 0.000 description 1
229940093612 zein Drugs 0.000 description 1
235000021241 α-lactalbumin Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- A61K38/166—Streptokinase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Wood Science & Technology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
Biotechnology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Cardiology (AREA)
Toxicology (AREA)
Biophysics (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Materials For Medical Uses (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

JP10501082A 1996-06-07 1997-06-06 修飾された第ｖｉｉ因子 Ceased JP2000513720A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/660,289		1996-06-07
US08/660,289 US5833982A (en)	1991-02-28	1996-06-07	Modified factor VII
PCT/DK1997/000251 WO1997047651A1 (en)	1996-06-07	1997-06-06	Modified factor vii

Publications (2)

Publication Number	Publication Date
JP2000513720A true JP2000513720A (ja)	2000-10-17
JP2000513720A5 JP2000513720A5 (2)	2005-03-10

Family

ID=24648892

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP10501082A Ceased JP2000513720A (ja)	1996-06-07	1997-06-06	修飾された第ｖｉｉ因子

Country Status (17)

Country	Link
US (2)	US5833982A (2)
EP (1)	EP0910580A1 (2)
JP (1)	JP2000513720A (2)
KR (1)	KR20000016415A (2)
CN (2)	CN1515318A (2)
AU (1)	AU735012B2 (2)
BR (1)	BR9709661A (2)
CA (1)	CA2256761A1 (2)
CZ (1)	CZ394698A3 (2)
HU (1)	HUP0003077A3 (2)
IL (1)	IL127099A0 (2)
NO (1)	NO985668L (2)
PL (1)	PL330365A1 (2)
RU (1)	RU2211704C2 (2)
UA (1)	UA68333C2 (2)
WO (1)	WO1997047651A1 (2)
ZA (1)	ZA975013B (2)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2005530752A (ja) *	2002-05-03	2005-10-13	ノボ　ノルディスク　アクティーゼルスカブ	修飾第ｖｉｉ因子の安定化された固体組成物
JP2008514677A (ja) *	2004-09-29	2008-05-08	ノボノルディスクヘルスケアアクチェンゲゼルシャフト	陰イオン交換物質からの分画溶出によるｖｉｉ因子ポリペプチドのバルクの精製
US7790852B2 (en)	2003-06-25	2010-09-07	Novo Nordisk Health Care A/G	Liquid composition of factor VII polypeptides
US7897734B2 (en)	2003-03-26	2011-03-01	Novo Nordisk Healthcare Ag	Method for the production of proteins
US8022031B2 (en)	2001-12-21	2011-09-20	Novo Nordisk Health Care A/G	Liquid composition of factor VII polypeptides
US8026214B2 (en)	2003-08-14	2011-09-27	Novo Nordisk Health Care Ag	Liquid, aqueous pharmaceutical compositions of factor VII polypeptides
US8299029B2 (en)	2002-06-21	2012-10-30	Novo Nordisk Health Care Ag	Stabilised solid compositions of factor VII polypeptides
US8536127B2 (en)	2003-05-23	2013-09-17	Novo Nordisk Healthcare Ag	Protein stabilization in solution
US8658597B2 (en)	2003-12-19	2014-02-25	Novo Nordisk Healthcare Ag	Stabilised compositions of factor VII polypeptides

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5997864A (en)	1995-06-07	1999-12-07	Novo Nordisk A/S	Modified factor VII
US20040087498A1 (en) *	1991-02-28	2004-05-06	Novo Nordisk Health Care Ag	Modified factor VII
AU8101698A (en) *	1997-07-18	1999-02-10	Novo Nordisk A/S	Use of fviia or fviiai for the treatment of adverse conditions related to the fviia mediated intracellular signalling pathway
US7247708B2 (en) *	1997-10-23	2007-07-24	Regents Of The University Of Minnesota	Modified vitamin K-dependent polypeptides
US6693075B1 (en) *	1997-10-23	2004-02-17	Regents Of The University Of Minnesota	Modified vitamin K-dependent polypeptides
US6747003B1 (en) *	1997-10-23	2004-06-08	Regents Of The University Of Minnesota	Modified vitamin K-dependent polypeptides
US6406488B1 (en) *	1998-08-27	2002-06-18	Heartstent Corporation	Healing transmyocardial implant
EP0987274A1 (en)	1998-09-15	2000-03-22	Hoechst Marion Roussel Deutschland GmbH	Factor VIIa Inhibitors
EP1059302A1 (en)	1999-06-08	2000-12-13	Aventis Pharma Deutschland GmbH	Factor VIIa inhibitors
US6924359B1 (en)	1999-07-01	2005-08-02	Yale University	Neovascular-targeted immunoconjugates
EP1095933A1 (en)	1999-10-30	2001-05-02	Aventis Pharma Deutschland GmbH	Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
DE60138364D1 (de) *	2000-02-11	2009-05-28	Bayer Healthcare Llc	Gerinnungsfaktor vii oder viia konjugate
EP2206720A1 (en) *	2000-04-12	2010-07-14	Human Genome Sciences, Inc.	Albumin fusion proteins
US7812132B2 (en)	2000-04-28	2010-10-12	Regents Of The University Of Minnesota	Modified vitamin K-dependent polypeptides
US7220837B1 (en)	2000-04-28	2007-05-22	Regents Of The University Of Minnesota	Modified vitamin K-dependent polypeptides
EP1162194A1 (en)	2000-06-06	2001-12-12	Aventis Pharma Deutschland GmbH	Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
WO2001097752A2 (en) *	2000-06-20	2001-12-27	The Trustees Of The University Of Pennsylvania	Compositions comprising urokinase for modulating muscle contractility and angiogenisis
US7160540B2 (en) *	2000-06-30	2007-01-09	Regents Of The University Of Minnesota	Methods for detecting activity of clottings factors
US6423826B1 (en)	2000-06-30	2002-07-23	Regents Of The University Of Minnesota	High molecular weight derivatives of vitamin K-dependent polypeptides
US20030211094A1 (en) *	2001-06-26	2003-11-13	Nelsestuen Gary L.	High molecular weight derivatives of vitamin k-dependent polypeptides
BR0115938A (pt)	2000-12-06	2003-12-23	Aventis Pharma Deustschland Gm	Derivados de guanidina e amidina com inibidores do fator xa
US6825323B2 (en) *	2001-01-10	2004-11-30	The United States Of America As Represented By The Secretary Of The Army	Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
US7235638B2 (en)	2001-03-22	2007-06-26	Novo Nordisk Healthcare A/G	Coagulation factor VII derivatives
MXPA03008590A (es) *	2001-03-22	2003-12-08	Novo Nordisk Healthcare Ag	Derivados del factor vii de coagulacion.
AU2002338487A1 (en) *	2001-05-02	2002-11-11	Novo Nordisk A/S	Modified fvii in treatment of ards
EP1270551A1 (en)	2001-06-26	2003-01-02	Aventis Pharma Deutschland GmbH	Urea derivatives with antiproteolytic activity
WO2003022122A2 (en) *	2001-09-10	2003-03-20	Florence Medical Ltd.	Individual ffr determination for lesions of a multi-lesioned blood vessel
US7173003B2 (en)	2001-10-10	2007-02-06	Neose Technologies, Inc.	Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
EP2042196B1 (en)	2001-10-10	2016-07-13	ratiopharm GmbH	Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
US7214660B2 (en)	2001-10-10	2007-05-08	Neose Technologies, Inc.	Erythropoietin: remodeling and glycoconjugation of erythropoietin
JP2005507008A (ja) *	2001-11-02	2005-03-10	ノボノルディスクヘルスケアアクチェンゲゼルシャフト	アポトーシスに関連した症状の治療のための、組織因子アゴニストまたは組織因子アンタゴニストの使用
EP1314733A1 (en)	2001-11-22	2003-05-28	Aventis Pharma Deutschland GmbH	Indole-2-carboxamides as factor Xa inhibitors
KR20040065278A (ko) *	2001-12-21	2004-07-21	노보 노르디스크 에이/에스	변경된 인자 ⅶ 폴리펩티드의 액체 조성물
EP1458407A1 (en) *	2001-12-21	2004-09-22	Novo Nordisk A/S	Liquid composition of modified factor vii polypeptides
SI1499719T1 (sl) *	2002-04-30	2011-03-31	Bayer Healthcare Llc	Polipeptidne variante faktorja VII ali VIIa
US20040009918A1 (en) *	2002-05-03	2004-01-15	Hanne Nedergaard	Stabilised solid compositions of modified factor VII
AU2003266931B2 (en) *	2002-09-30	2010-01-21	Bayer Healthcare Llc	FVII or FVIIa variants having increased clotting activity
US7358268B2 (en)	2002-12-04	2008-04-15	Sanofi-Aventis Deutschland Gmbh	Imidazole derivatives as factor Xa inhibitors
US7429581B2 (en)	2002-12-23	2008-09-30	Sanofi-Aventis Deutschland Gmbh	Pyrazole-derivatives as factor Xa inhibitors
US20040176704A1 (en) *	2003-03-04	2004-09-09	Stevens Timothy A	Collection device adapted to accept cartridge for point of care system
RU2005132164A (ru) *	2003-03-18	2006-06-10	Ново Нордиск Хелт Кэр Аг (Ch)	Жидкие, водные фармацевтические композиции полипептидов фактора vii
DK1608745T3 (da) *	2003-03-20	2009-06-15	Bayer Healthcare Llc	FVII eller FVIIa-Varianter
EP2055189A1 (en)	2003-04-09	2009-05-06	Neose Technologies, Inc.	Glycopegylation methods and proteins/peptides produced by the methods
US20040202726A1 (en) *	2003-04-10	2004-10-14	Deshay Samuel L.	Topical blood pressure composition
US7317027B2 (en)	2003-05-19	2008-01-08	Sanofi-Aventis Deutschland Gmbh	Azaindole-derivatives as factor Xa inhibitors
EP1479680A1 (en)	2003-05-19	2004-11-24	Aventis Pharma Deutschland GmbH	Azaindole derivatives as Factor Xa inhibitors
EP1479675A1 (en)	2003-05-19	2004-11-24	Aventis Pharma Deutschland GmbH	Indazole-derivatives as factor Xa inhibitors
US7223780B2 (en)	2003-05-19	2007-05-29	Sanofi-Aventis Deutschland Gmbh	Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
US7741341B2 (en)	2003-05-19	2010-06-22	Sanofi-Aventis Deutschland Gmbh	Benzimidazole-derivatives as factor Xa inhibitors
EP1479677A1 (en)	2003-05-19	2004-11-24	Aventis Pharma Deutschland GmbH	New indole derivatives as factor xa inhibitors
US7029675B1 (en) *	2003-06-04	2006-04-18	Shu-Wha Lin	Hepsin antagonist and methods of use
NZ573412A (en) *	2003-06-19	2010-09-30	Maxygen Holdings Ltd	Factor VII or VIIa Gla domain variants
EP1644030B1 (en) *	2003-07-01	2009-10-28	Novo Nordisk Health Care AG	Liquid, aqueous pharmaceutical composition of factor vii polypeptides
WO2005012484A2 (en)	2003-07-25	2005-02-10	Neose Technologies, Inc.	Antibody-toxin conjugates
US20080305992A1 (en)	2003-11-24	2008-12-11	Neose Technologies, Inc.	Glycopegylated erythropoietin
EP1568698A1 (en)	2004-02-27	2005-08-31	Aventis Pharma Deutschland GmbH	Pyrrole-derivatives as factor Xa inhibitors
US20080176790A1 (en)	2004-10-29	2008-07-24	Defrees Shawn	Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
US9029331B2 (en)	2005-01-10	2015-05-12	Novo Nordisk A/S	Glycopegylated granulocyte colony stimulating factor
US20070154992A1 (en)	2005-04-08	2007-07-05	Neose Technologies, Inc.	Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20070105755A1 (en)	2005-10-26	2007-05-10	Neose Technologies, Inc.	One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en)	2005-11-03	2007-05-18	Neose Technologies, Inc.	Nucleotide sugar purification using membranes
ES2516694T3 (es)	2006-07-21	2014-10-31	Ratiopharm Gmbh	Glicosilación de péptidos a través de secuencias de glicosilación con unión en O
US8969532B2 (en)	2006-10-03	2015-03-03	Novo Nordisk A/S	Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
KR20100016160A (ko)	2007-04-03	2010-02-12	바이오제너릭스 에이지	글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법
WO2008154639A2 (en)	2007-06-12	2008-12-18	Neose Technologies, Inc.	Improved process for the production of nucleotide sugars
KR101582841B1 (ko)	2008-02-27	2016-01-11	노보 노르디스크 에이/에스	콘쥬게이트된 인자 ｖｉｉｉ 분자
WO2010071894A2 (en)	2008-12-19	2010-06-24	Baxter International Inc.	Tfpi inhibitors and methods of use
AU2010290131C1 (en)	2009-08-24	2015-12-03	Amunix Operating Inc.	Coagulation factor VII compositions and methods of making and using same
AU2011227714B2 (en)	2010-03-19	2014-09-04	Takeda Pharmaceutical Company Limited	TFPI inhibitors and methods of use
KR101294351B1 (ko) *	2010-05-27	2013-08-07	동국대학교 산학협력단	뇌혈전 형광영상기술을 이용한 뇌졸중 동물모델의 뇌경색 영역의 크기 예측 방법
CA2864126A1 (en)	2012-02-15	2013-08-22	Biogen Idec Ma Inc.	Recombinant factor viii proteins
BR112014020694A2 (pt)	2012-02-15	2018-05-08	Amunix Operating Inc.	proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
WO2013141965A1 (en)	2012-03-21	2013-09-26	Baxter International Inc.	Tfpi inhibitors and methods of use
US10548953B2 (en)	2013-08-14	2020-02-04	Bioverativ Therapeutics Inc.	Factor VIII-XTEN fusions and uses thereof
AU2016297178A1 (en) *	2015-07-22	2018-01-25	Iconic Therapeutics, Inc.	Methods for treating disorders associated with angiogenesis and neovascularization
BR112018002150A2 (pt)	2015-08-03	2018-09-18	Bioverativ Therapeutics Inc	proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
ES2856968T3 (es)	2016-01-15	2021-09-28	Rigshospitalet	Adquisición de imágenes de TEP cuantitativas de la expresión de factor tisular usando factor VII inhibido en el punto activo y marcado con 18F
WO2018091058A1 (en)	2016-11-17	2018-05-24	Rigshospitalet	177-lu labeled active site inhibited factor vii
IL319473A (en)	2016-12-02	2025-05-01	Bioverativ Therapeutics Inc	Methods for treating hemophilic arthritis using chimeric blood clotting factors
BR112020022164A2 (pt)	2018-05-18	2021-02-02	Bioverativ Therapeutics Inc.	métodos de tratamento de hemofilia a

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4775624A (en) *	1985-02-08	1988-10-04	Eli Lilly And Company	Vectors and compounds for expression of human protein C
GR860984B (en) *	1985-04-17	1986-08-18	Zymogenetics Inc	Expression of factor vii and ix activities in mammalian cells
ATE74164T1 (de) *	1985-04-22	1992-04-15	Genetics Inst	Herstellung mit hoher leistung des aktivfaktors ix.
US4959318A (en) *	1985-06-27	1990-09-25	Zymogenetics, Inc.	Expression of protein C
US4829052A (en) *	1986-06-11	1989-05-09	Monsanto Company	Serine protease inhibitors
US5258288A (en) *	1986-07-25	1993-11-02	Genzyme Corporation	Vector containing DNA encoding mature human protein S
EP0278727A3 (en)	1987-02-10	1990-03-14	Glaxo Group Limited	1-(4-amino-3-chloro-5-trifluoromethylphenyl)-2-(substituted amino)ethanol derivatives and their use in the treatment of respiratory disease
FR2619314B1 (fr) *	1987-08-11	1990-06-15	Transgene Sa	Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) *	1987-08-28	1991-02-19	Davie Earl W	DNA preparation of Christmas factor and use of DNA sequences
US5023236A (en) *	1988-04-07	1991-06-11	Corvas, Inc.	Factor VII/VIIA active site inhibitors
US5258180A (en) *	1988-09-02	1993-11-02	Genetech, Inc.	Tissue plasminogen activator having fibrin specific properties and deletion of amino acids 466-970, compositions and methods of treatment
EP0391999A4 (en) *	1988-09-23	1991-03-13	Corvas, Inc.	Peptidyl inhibitors of the initiation of coagulation
US5120537A (en) *	1989-06-14	1992-06-09	Oklahoma Medical Research Foundation	Factor xa based anticoagulant compositions
US5190919A (en) *	1989-11-13	1993-03-02	Board Of Regents, The University Of Texas System	Antihemostatic factor vii peptides
JP3330932B2 (ja) *	1990-01-29	2002-10-07	ノボノルディスクヘルスケアアクチェンゲゼルシャフト	抗凝固剤タンパク質
US5278144A (en) *	1990-09-04	1994-01-11	Cor Therapeutics, Inc.	Antithrombosis agents
US5861374A (en)	1991-02-28	1999-01-19	Novo Nordisk A/S	Modified Factor VII
EP1479395A1 (en) *	1991-02-28	2004-11-24	Novo Nordisk A/S	Modified factor VII
US5817788A (en)	1991-02-28	1998-10-06	Zymogenetics, Inc.	Modified factor VII
US5788965A (en)	1991-02-28	1998-08-04	Novo Nordisk A/S	Modified factor VII
RU2022561C1 (ru) *	1991-03-05	1994-11-15	Харьковский государственный университет им.А.М.Горького	Противоишемическое средство
US5326559A (en) *	1991-05-16	1994-07-05	Miller D Douglas	Treatment of accelerated atheosclerosis with interleukin-2 receptor targeted molecules
US5419760A (en) *	1993-01-08	1995-05-30	Pdt Systems, Inc.	Medicament dispensing stent for prevention of restenosis of a blood vessel
GB9301093D0 (en) *	1993-01-20	1993-03-10	Rca Thomson Licensing Corp	Digital video tape recorder for digital hdtv
AU703110B2 (en) *	1993-05-21	1999-03-18	Novo Nordisk A/S	Modified factor VII
US5648331A (en) *	1994-08-26	1997-07-15	G.D. Searle & Co.	Method of inhibiting tissue ischemia and reperfusion injury

1996
- 1996-06-07 US US08/660,289 patent/US5833982A/en not_active Expired - Fee Related
1997
- 1997-06-06 IL IL12709997A patent/IL127099A0/xx unknown
- 1997-06-06 JP JP10501082A patent/JP2000513720A/ja not_active Ceased
- 1997-06-06 EP EP97925917A patent/EP0910580A1/en not_active Withdrawn
- 1997-06-06 CZ CZ983946A patent/CZ394698A3/cs unknown
- 1997-06-06 WO PCT/DK1997/000251 patent/WO1997047651A1/en not_active Ceased
- 1997-06-06 RU RU99100089/14A patent/RU2211704C2/ru not_active IP Right Cessation
- 1997-06-06 PL PL97330365A patent/PL330365A1/xx unknown
- 1997-06-06 CN CNA031066089A patent/CN1515318A/zh active Pending
- 1997-06-06 ZA ZA9705013A patent/ZA975013B/xx unknown
- 1997-06-06 UA UA98126442A patent/UA68333C2/uk unknown
- 1997-06-06 CA CA002256761A patent/CA2256761A1/en not_active Abandoned
- 1997-06-06 HU HU0003077A patent/HUP0003077A3/hu unknown
- 1997-06-06 BR BR9709661-0A patent/BR9709661A/pt not_active IP Right Cessation
- 1997-06-06 CN CN97195294A patent/CN1131872C/zh not_active Expired - Fee Related
- 1997-06-06 AU AU30906/97A patent/AU735012B2/en not_active Ceased
- 1997-06-06 KR KR1019980709998A patent/KR20000016415A/ko not_active Ceased
1998
- 1998-11-10 US US09/189,607 patent/US6168789B1/en not_active Expired - Fee Related
- 1998-12-04 NO NO985668A patent/NO985668L/no not_active Application Discontinuation

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8461116B2 (en)	2001-12-21	2013-06-11	Novo Nordisk Healthcare Ag	Liquid composition of factor VII polypeptides
US8022031B2 (en)	2001-12-21	2011-09-20	Novo Nordisk Health Care A/G	Liquid composition of factor VII polypeptides
JP2005530752A (ja) *	2002-05-03	2005-10-13	ノボ　ノルディスク　アクティーゼルスカブ	修飾第ｖｉｉ因子の安定化された固体組成物
US8729022B2 (en)	2002-06-21	2014-05-20	Novo Nordisk Healthcare Ag	Stabilised solid compositions of factor VII polypeptides
US8299029B2 (en)	2002-06-21	2012-10-30	Novo Nordisk Health Care Ag	Stabilised solid compositions of factor VII polypeptides
US8084587B2 (en)	2003-03-26	2011-12-27	Novo Nordisk Health Care Ag	Method for the production of proteins
US7897734B2 (en)	2003-03-26	2011-03-01	Novo Nordisk Healthcare Ag	Method for the production of proteins
US8536127B2 (en)	2003-05-23	2013-09-17	Novo Nordisk Healthcare Ag	Protein stabilization in solution
US7790852B2 (en)	2003-06-25	2010-09-07	Novo Nordisk Health Care A/G	Liquid composition of factor VII polypeptides
US8026214B2 (en)	2003-08-14	2011-09-27	Novo Nordisk Health Care Ag	Liquid, aqueous pharmaceutical compositions of factor VII polypeptides
US8318904B2 (en)	2003-08-14	2012-11-27	Novo Nordisk Health Care Ag	Liquid, aqueous pharmaceutical compositions of factor VII polypeptides
US8658597B2 (en)	2003-12-19	2014-02-25	Novo Nordisk Healthcare Ag	Stabilised compositions of factor VII polypeptides
JP2013056891A (ja) *	2004-09-29	2013-03-28	Novo Nordisk Health Care Ag	陰イオン交換物質からの分画溶出によるｖｉｉ因子ポリペプチドのバルクの精製
JP2008514677A (ja) *	2004-09-29	2008-05-08	ノボノルディスクヘルスケアアクチェンゲゼルシャフト	陰イオン交換物質からの分画溶出によるｖｉｉ因子ポリペプチドのバルクの精製
JP2016006074A (ja) *	2004-09-29	2016-01-14	ノボノルディスクヘルスケアアクチェンゲゼルシャフト	陰イオン交換物質からの分画溶出によるｖｉｉ因子ポリペプチドのバルクの精製

Also Published As

Publication number	Publication date
IL127099A0 (en)	1999-09-22
CA2256761A1 (en)	1997-12-18
HUP0003077A2 (hu)	2000-12-28
KR20000016415A (ko)	2000-03-25
CN1515318A (zh)	2004-07-28
ZA975013B (en)	1997-12-08
US5833982A (en)	1998-11-10
UA68333C2 (en)	2004-08-16
AU3090697A (en)	1998-01-07
RU2211704C2 (ru)	2003-09-10
WO1997047651A1 (en)	1997-12-18
NO985668D0 (no)	1998-12-04
NO985668L (no)	1999-02-04
HUP0003077A3 (en)	2003-01-28
CN1221427A (zh)	1999-06-30
EP0910580A1 (en)	1999-04-28
US6168789B1 (en)	2001-01-02
PL330365A1 (en)	1999-05-10
CZ394698A3 (cs)	1999-04-14
AU735012B2 (en)	2001-06-28
BR9709661A (pt)	2000-04-25
CN1131872C (zh)	2003-12-24

Legal Events

Date	Code	Title	Description
2004-06-24	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040607
2004-07-08	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040622
2008-03-18	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080318
2008-09-11	A313	Final decision of rejection without a dissenting response from the applicant	Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20080812
2008-09-30	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080930

Publication	Publication Date	Title
JP2000513720A (ja)	2000-10-17	修飾された第ｖｉｉ因子
US5788965A (en)	1998-08-04	Modified factor VII
US5817788A (en)	1998-10-06	Modified factor VII
US6183743B1 (en)	2001-02-06	Modified factor VII
US5861374A (en)	1999-01-19	Modified Factor VII
MXPA97002951A (en)	1998-02-01	Factor vii modific
AU703110B2 (en)	1999-03-18	Modified factor VII
JP4455802B2 (ja)	2010-04-21	ヒト第ｖｉｉ凝固因子変異型
JP4361728B2 (ja)	2009-11-11	ヒト凝固因子ｖｉｉ変異型
US6039944A (en)	2000-03-21	Modified Factor VII
US20040087498A1 (en)	2004-05-06	Modified factor VII
Stern et al.	1988	Endothelium and the regulation of coagulation
RU2214833C2 (ru)	2003-10-27	Модифицированный фактор vii
AU766827B2 (en)	2003-10-23	Modified factor VII
AU5940799A (en)	2000-02-17	Modified factor VII
MXPA98010211A (en)	1999-09-20	Factor vii modific
AU2004200261A1 (en)	2004-02-19	Modified Factor VII
UA48149C2 (uk)	2002-08-15	Спосіб інгібування активності фактора тканини, спосіб пригнічення відкладення тромбоцитів, спосіб пригнічення судинного рестенозу, спосіб лікування гострої закупорки коронарної артерії за допомогою модифікованого фактора vii